Drug – bio-affecting and body treating compositions – Whole live micro-organism – cell – or virus containing – Animal or plant cell
Reexamination Certificate
2008-02-01
2009-12-29
Belyavskyi, Michail A (Department: 1644)
Drug, bio-affecting and body treating compositions
Whole live micro-organism, cell, or virus containing
Animal or plant cell
C424S143100, C424S572000, C514S885000
Reexamination Certificate
active
07638121
ABSTRACT:
A method of preparing a human recipient for a graft from a human which includes: administering donor peripheral blood progenitor cells to the recipient, and providing a minimally ablative.
REFERENCES:
patent: 5474771 (1995-12-01), Lederman et al.
patent: 5514364 (1996-05-01), Ildstad
patent: 5635156 (1997-06-01), Ildstad
patent: 5806529 (1998-09-01), Reisner et al.
patent: 5817311 (1998-10-01), Bazin et al.
patent: 5876692 (1999-03-01), Ildstad
patent: 5876708 (1999-03-01), Sachs
patent: 6006752 (1999-12-01), Sykes
patent: 6558662 (2003-05-01), Sykes et al.
patent: 7332157 (2008-02-01), Sykes
patent: 93/06852 (1993-04-01), None
patent: 95/11692 (1995-05-01), None
patent: 95/24217 (1995-09-01), None
patent: 97/24217 (1997-11-01), None
patent: 97/41863 (1997-11-01), None
patent: 99/03502 (1999-01-01), None
patent: 99/25367 (1999-05-01), None
Benkerrou et al., “Anti-B-Cell Monoclonal Antibody Treatment of Sever Posttranslpant B-Lymphoproliferative Disorder: Prognostic Factors and Long-Term Outcome,”Blood,vol. 92:3137-3147 (1998).
Colson et al., “A Nonlethal Conditioning Approach to Achieve Durable Multillineage Mixed Chimerism and Tolerance Across Major, Minor, and Hematopoietic Histocompatibility Barriers,”J. Immunology,vol. 153:4179-4188 (1995).
Emerson, “Ex Vivo Expansion of Hematopoietic Precursors, Progenitors, and Stem Cells: The Next Generation of Cellular Therapies,”Blood,vol. 87:3082-3088 (1996).
Kawai et al., “Mixed Allogeneic Chimerism and Renal Allograft Tolerance in Cynomolgus Monkeys,”Transplantation,vol. 59:256-262 (1995).
Kimikawa et al., “Modifications of the Conditioning Regimen for Achieving Mixed Chimerism and Donor-Specific Tolerance in Cynomolgus Monkeys,”Transplantation,vol. 64:709-716 (1997).
Kimikawa et al.,“ Mixed Chimerism and Transplantation Tolerance Induced by a Nonlethal Preparative Regimen in Cynomolgus Monkeys,”Trans. Proc.,vol. 29:1218 (1997).
Kirk et al., “CTLA4-Ig and anti-CD40 ligand prevent renal allograft rejection in primates,”Porc. Natl. Acad. Sci.,vol. 94:8789-8794 (1997).
Li et al., “Mixed Allogeneic Chimerism Achieved by Lethal and Nonlethal Conditioning Approaches Induces Donor-Specific Tolerance to Simultaneous Islet Allografts,”Transplantation,vol. 60:523-529 (1995).
Manilay et al., “Intrathymic Deletion of Alloreactive T Cells in Mixed Bone Marrow Chimeras Prepared With a Nonmyeloablative Conditioning Regimen,”Transplantation,vol. 66:96-102 (1998).
Monaco et al., “Possible active enhancement of human cadaver renal allograft with antilymphocyte serum (ALS) and donor bone marrow: Case report of an initial attempt,”Surgery,vol. 79:384-392 (1976).
Petzer et al., “Self-renewal of primitive hematopoietic cells (long-term-culture-initiating cells) in vitro and their expansion in defined medium,”Proc. Natl. Acad. Sci. USA,vol. 93:1470-1474 (1996).
Schad et al., “Anti-CD2 Monoclonal Antibody Elicits Specific Alloantigen Hyporesponsiveness,”Faseb Journal,vol. 10:A1313 (1996).
Sharabi et al., “Engraftment of Allogeneic Bone Marrow Following Administration of Anti-T Cell Monoclonal Antibodies and Low-Dose Irradiation,”Trans. Proc.,vol. 21:233-235 (1989).
Sharabi et al., “Mixed Chimerism and Permanent Specific Transplantation Tolerance Induced by a Nonlethal Preparative Regiment,”J. Exp. Med.,vol. 169:493-502 (1989).
Storb et al., “Stable Mixed Hematopoietic Chimerism in DLA-Identical Littermate Dogs Given Sublethal Total Body Irradiation Before and Pharmacological Immunosuppression After Marrow Transplantation,”Blood,vol. 89:3048-3054 (1997).
Sykes et al., “Xenograft Tolerance,”Immunological Reviews,vol. 141:245-276 (1994).
Sykes et al., “Induction of high levels of allogeneic hematopoietic reconstitution and donor-specific tolerance without myelosuppressive conditioning,”Nature Medicine,vol. 3:783-787 (1997).
Wekerle et al., “Extrathymic T Cell Deletion and Allogeneic Stem Cell Engraftment Induced With Costimulatory Blockade Is Followed by Central T Cell Tolerance,”Journal of Experimental Medicine,vol. 187:2037-2044 (1998).
Wekerle et al., “Anti-CD154 or CTLA41g Obviates the Need for Thymic Irradiation in a Non-Myeloablative Conditioning Regimen for the Induction of Mixed Hematopoietic Chimerism and Tolerance,”Transplantation,vol. 68:1348-1355 (1999).
Woodward et al., “Blockade of Multiple Costimulatory Receptors Induces Hyporesponsiveness,”Transplantation,vol. 62:1011-1018 (1996).
Xia et al., “Rat monoclonal Antibodies Specific for Human T. Lymphocytes,”In Rat Hybridomas and Rat Monoclonal Antibodies,Ed. H. Bzin, CRC Press Inc., Boca Raton, Florida, 309-322 (1990).
Zandstra et al., “Expansion of Hematopoietic Progenitor Cell Populations in Stirred Suspension Bioreactors of Normal Human Bone Marrow Cells,”Bio/Technology,vol. 12:909:914 (1994).
Belyavskyi Michail A
Choate Hall & Stewart LLP
Furman Margo H.
The General Hospital Corporation
LandOfFree
Methods for human allografting does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for human allografting, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for human allografting will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4090158